Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 333-336

  Secchiero, Paola ^a   Gonelli, Arianna ^a   Corallini, Federica ^a   Ceconi, Claudio ^b   Ferrari, Roberto ^b   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS   (Italy)

Author keywords

Acute myocardial infarction; MMP2; TIMP2; TRAIL

Indexed keywords

GELATINASE A; GELATINASE B; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RECOMBINANT PROTEIN;

ACUTE HEART INFARCTION; APOPTOSIS; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; SUPERNATANT; ANTERIOR MYOCARDIAL INFARCTION; BLOOD; DRUG EFFECTS; METABOLISM;

ANTERIOR WALL MYOCARDIAL INFARCTION; APOPTOSIS; HUMANS; MATRIX METALLOPROTEINASE 2; RECOMBINANT PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954310552     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.02.024     Document Type: Article

References (15)

1. Secchiero P., Corallini F., Ceconi C., et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS ONE 2009, 4:e4442.
2. Niessner A., Hohensinner P.J., Rychli K., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009, 30:789-796.
3. Mori K., Ikari Y., Jono S., et al. Association of serum TRAIL level with coronary artery disease. Thromb Res December 22, 2009, [Epub ahead of print].
4. Zauli G., Secchiero P. The role of theTRAIL/TRAIL-receptors system in hematopoiesis and endothelial cell biology. Cyt Growth Fact Rev 2006, 17:245-257.
5. Secchiero P., Corallini F., Beltrami A.P., et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis November 10, 2009, [Epub ahead of print].
6. Zauli G., Pandolfi A., Gonelli A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003, 92:732-740.
7. Secchiero P., Corallini F., di Iasio M.G., et al. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005, 105:3413-3419.
8. Secchiero P., Candido R., Corallini F., et al. Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 2006, 114:1522-1530.
9. George J., Patal S., Wexler D., et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of not matrix metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005, 150:484-487.
10. Phatharajaree W., Phrommintikul A., Chattipakorn N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol 2007, 23:727-733.
11. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., Kaski J.C. High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction. Atherosclerosis 2008, 196:365-371.
12. Dhillon O.S., Khan S.Q., Narayan H.K., et al. Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome. Clin Sci (Lond) July 8, 2009, [Epub ahead of print].
13. Zauli G., Re M.C., Furlini G., Giovannini M., La Placa M. Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 1992, 73:417-421.
14. McQuibban G.A., Butler G.S., Gong J.H., et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell derived factor-1. J Biol Chem 2001, 276:43503-43508.
15. Niormoi O., Mills L., Bar-Eli M. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 2003, 10:558-569.